**In the claims**:

Claims 1 to 28 (cancelled).

Claim 29 (currently amended)   A carbohydrate peptide conjugate which

induces an antibody response against a carbohydrate tumor antigen, said conjugate

having a carbohydrate content comprised between 37% (w/w) and 90% (w/w), and said

conjugate being selected from the group consisting of the conjugates of the following

formulae (a) to (d)

```
  B - T                T - B              T                    T
       \           /                       \              /
        K - K - K                            K - K - K
  B - T /          \    T - B           B /             \    B
       (a)                                      (c)

  B - T            T - B                 T              T
    |                |                    \            /
  B - T - K        K — T - B           B — K         K — B
       \         /                          \          |
        K - K - K                           K - K - K
       /         \                           |         |
  B - T - K        K — T - B           B — K         K — T
    |                |                    |            |
  T - B            T - B                 T            B
       (b)                                      (d)
```

wherein:

-   K is a lysyl residue;

-   T is A CD4$^+$ cell peptide epitope;

-   B is a carbohydrate moiety consisting of a tumor antigen, or a carbohydrate

    derivative thereof.

2

Claim 30 (previously presented)   A conjugate of Claim 29 wherein B is galactosyl.

Claim 31 (cancelled).

Claim 32 (previously presented)   A conjugate of Claim 29 wherein B is a galactosyl residue and is substituted with a glycosyl residue.

Claims 33 – 37 (cancelled).

Claim 38 (previously presented)   A conjugate of Claim 29 wherein B is selected from the group consisting of Tn antigen, di-Tn antigen, Tri-Tn antigen, T^* antigen and hexa-Tn antigen.

Claim 39 (previously presented)   A pharmaceutical composition comprising the conjugate of Claim 29 and a suitable carrier and adjuvant.

Cancel **Claim 40.**

Claim 41 (cancelled).

Claim 42 (currently amended)   An immunogenic composition comprising at least one carbohydrate peptide conjugate of Claim 29 wherein said composition is capable of increasing the survival of a <u>colon</u> tumor bearing human or animal.

Claim 43 (previously presented)   An immunogenic composition comprising at least one carbohydrate conjugate of Claim 42 wherein said conjugate comprises different carbohydrate antigens.

Claim 44 (previously presented)   A method of inducing an immune response to at least one member of the group consisting of B-cells and CD4$^+$ T-cells in a human or animal body, wherein the conjugate of Claim 29 is administered to said human or animal body.

Claims 45 - 46 (cancelled).

Cancel **Claim 47** and add Claims **48** to **50**.

Claim 48 (new)   A conjugate of Claim 29 having a carbohydrate content comprised between 37% (w/w) and 38% (w/w).

Claim 49 (new)   A conjugate of Claim 29 having a carbohydrate content of 37% (w/w).

Claim 50 (new)   A conjugate of Claim 29 having a carbohydrate content of

38% (w/w).